Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma

Blood

Volumn 91, Issue 3, 1998, Pages 806-812

  Seidel, Carina ^a   Børset, Magne ^b   Turesson, Ingemar ^b   Abildgaard, Niels ^b   Sundan, Anders ^b   Waage, Anders ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; COLLAGEN TYPE 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MELPHALAN; OSTEOCALCIN; PREDNISONE; SCATTER FACTOR;

ADULT; AGED; ARTICLE; BONE DESTRUCTION; CONTROLLED STUDY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SERUM; SURVIVAL RATE;

EID: 0032006829     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.3.806     Document Type: Article

References (43)

1. Nakamura T, Nawa K, Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122:1450, 1984
2. Zarnegar R, Michalopoulos GK: The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis. J Cell Biol 129:1177, 1995
3. Stoker M, Gherardi E, Perryman M, Gray J: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:239, 1987
4. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802, 1991
5. Galimi F, Bagnara GP, Bonsi L, Cottone E, Follenzi A, Simeone A, Comoglio PM: Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J Cell Biol 127:1743, 1994
6. Kmiecik TE, Keller JR, Rosen E, Vande Woude GF: Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood 80:2454, 1992
7. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629, 1992
8. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tomigana T: Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1:1031, 1995
9. Sato T, Hakeda Y, Yamaguchi Y, Mano H, Tezuka K, Matsumoto K, Nakamura T, Mori Y, Yoshizawa K, Sumitani K, et al: Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6). J Cell Physiol 164:197, 1995
10. Fuller K, Owens J, Chambers TJ: The effect of hepatocyte growth factor on the behaviour of osteoclasts. Biochem Biophys Res Commun 212:334, 1995
11. Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ, Comoglio PM: Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 93:7644, 1996
12. Børset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A: Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 271:24655, 1996
13. Børset M, Hjorth Hansen H, Seidel C, Sundan A, Waage A: Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88:3998, 1996
14. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group. Ann Intern Med 124:212, 1996
15. Durie BGM, Salomon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842, 1975
16. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L: Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haematol 96:103, 1997
17. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
18. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Reports 50:163, 1966
19. Cox DR: Regression models and life tables. J R Stat Soc B34:187, 1972
20. Salmon SE, Smith BA: Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest: 1114, 1970
21. Tienhaara A, Pulkki K, Mattila K, Irjala K, Pelliniemi TT: Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol 86:391, 1994
22. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R: Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 85:765, 1995
23. Bataille R, Jourdan M, Zhang X, Klein B: Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008, 1989
24. Nachbaur DM, Herold M, Maneschg A, Huber H: Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters. Ann Hematol 62:54, 1991
25. Brown R, Joshua D, Uhr E, Snowdon L, Gibson J: The use of a commercially available immunoassay to determine the level of interleukin-6 in the serum of patients with multiple myeloma. Leuk Lymphoma 5:151, 1991
26. Kyrtsonis MC, Dedoussis G, Zervas C, Perifanis V, Baxevanis C, Stamatelou M, Maniatis A: Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol 93:398, 1996
27. Ohtani K, Ninomiya H, Hasegawa Y, Kobayashi T, Kojima H, Nagasawa T, Abe T: Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Br J Haematol 91:116, 1995
28. Pulkki K, Pellinemi T-T, Rajamaki A, Tienharaara A, Laakso M, Lahtinen R: Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 92:370, 1996
29. Musto P, Fusilli S, Carotenuto M: Plasma cell acid phosphatase and prognosis in multiple myeloma. Leuk Lymphoma 14:497, 1994
30. Thavasu PW, Ganjoo RK, Maidment SA, Love SB, Williams AH, Malplas JS, Balkwill FR: Multiple myeloma: An immunoclinical study of disease and response to treatment. Hematol Oncol 13:69, 1995
31. Durie BG, Stock Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA: Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: A Southwest Oncology Group Study. Blood 75:823, 1990
32. Bataille R, Grenier J, Sany J: Beta-2-microglobulin in myeloma: Optimal use for staging, prognosis, and treatment - A prospective study of 160 patients. Blood 63:468, 1984
33. Bartl R, Frisch B, Diem H, Mundel M, Nagel D, Lamerz R, Fateh Moghadam A: Histologic, biochemical, and clinical parameters for monitoring multiple myeloma. Cancer 68:2241, 1991
34. van Dobbenburgh OA, Rodenhuis S, Ockhuizen T, Weltevreden E, Houwen B, Fidler V, Meijer S, Marrink J: Serum beta 2-microglobulin: A real improvement in the management of multiple myeloma? Br J Haematol 61:611, 1985
35. Boccadoro M, Omede P, Frieri R, Battaglio S, Gallone G, Massaia M, Redoglia V, Pileri A: Multiple myeloma: Beta-2-microglobulin is not a useful follow-up parameter. Acta Haematol 82:122, 1989
36. Sugimura K, Lee CCR, Kim T, Goto T, Kasai S, Harimoto K, Yamagami S, Kishimoto T: Production of hepatocyte growth factor is increased in chronic renal failure. Nephron 75:7, 1996
37. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 2348, 1974
38. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J: Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry. J Bone Miner Res 8:127, 1993
39. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF: Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: Relation to calcium kinetics. Bone Miner 24:81, 1994
40. Blade J, Lopez Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C: Impact of response to treatment on survival in multiple myeloma: Results in a series of 243 patients. Br J Haematol 88:117, 1994
41. Oivanen TM: Plateau phase in multiple myeloma: An analysis of long-term follow-up of 432 patients. Finnish Leukaemia Group. Br J Haematol 92:834, 1996
42. Joshua DE, Snowdon I, Gibson J, Iland H, Brown R, Warburton P, Kulkarni A, Vincent P, Young G, Gatneby P, Basten A, Kronenberg H: Multiple Myeloma: Plateau phase revisited. Hem Rev 5:59, 1991
43. Taniguchi T, Kitamura M, Arai K, Iwasaki Y, Yamamoto Y, Igari A, Toi M: Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer 75:673, 1997